Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>IMS</strong> COM PANY PRO FILES TAKEDA<br />
tion). This had been one of three drugs crowned by Takeda as ‘jew els’ in the pipe line and an tic i pated to<br />
plug the loom ing sales gap from pat ent expiration of core products in the coming years.<br />
MATUZUMAB (EMD 72000), a hu man ized monoclonal an ti body tar geted to epi der mal growth fac tor re -<br />
cep tor (EGFR) was in phase II tri als in the US, Eu rope and Ja pan with Takeda for colorectal can cer,<br />
nonsmall cell lung can cer (NSCLC), and gas tric can cer in 2007. In Feb ru ary 2008, Takeda and Merck<br />
KGaA an nounced the dis con tinu a tion of the de vel op ment of matuzumab for the treat ment of can cer af ter<br />
it did not meet its pre de fined endpoints of activity.<br />
ARXXANT (ruboxistaurin,) a pro tein kinase C beta (PKCb) in hib i tor, orig i nally de vel oped by Lilly (USA)<br />
was in phase II de vel op ment with Takeda and Lilly in Ja pan. In Au gust 2007 Lilly and Takeda an nounced<br />
that they have ter mi nated their agree ment signed in De cem ber 2003 to jointly de velop and mar ket<br />
ruboxistaurin in Ja pan. The de ci sion fol lowed an anal y sis of the over all re sults from di a betic pe riph eral<br />
neu rop a thy and di a betic macular edema phase II tri als, which did not meet their pre-spec i fied go/no go<br />
decision criteria for phase III trials.<br />
TAK 375 was in phase III tri als for Alz hei mer’s sleep/wake up dis tur bance. This study was dis con tin ued<br />
in 2007 how ever af ter the num ber of en rolled pa tients meet ing in clu sion cri te ria did not reach an ex -<br />
pected level. In 2003, re sults from early stage tri als dem on strated that TAK 375 is a highly se lec tive ML-1<br />
re cep tor ag o nist. A month later, Takeda pre sented data from a phase I study eval u at ing the safety,<br />
pharmacokinetics and pharmacodynamics of a sin gle oral dose of its melatonin ag o nist. In a study on 60<br />
adults re ceiv ing a dose rang ing from four to 64 mg, the fre quency of ad verse events was similar for TAK<br />
375 and placebo.<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 79
Change language